Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Scott Borinstein"'
Autor:
William Cutrer, Rebekah Brown, Geoffrey Fleming, Jill Simmons, Scott Borinstein, William Cooper, Joseph Gigante
Publikováno v:
MedEdPORTAL, Vol 10 (2014)
Abstract Introduction The development of junior faculty drives the success of an academic institutional department through furthering individual career success. Mentorship is central in this early development and results in improved job satisfaction
Externí odkaz:
https://doaj.org/article/bc1f2f8adf944b7aaaca10336164dfad
Autor:
Katherine A. Minson, Pinki Prasad, Susan Vear, Scott Borinstein, Richard Ho, Jennifer Domm, Haydar Frangoul
Publikováno v:
Case Reports in Hematology, Vol 2013 (2013)
Several cytogenetic abnormalities identified in patients with childhood acute lymphocytic leukemia (ALL) have been associated with a poor prognosis. There are several case reports in the literature describing t(17;19) in children with ALL. This trans
Externí odkaz:
https://doaj.org/article/6fca80804d0d4e49aa61a9a7ee0fe2cf
Autor:
Julie R. Park, Peter C. Adamson, Brenda Weigel, Alice Chen, Darrell J. Yamashiro, Ashish M. Ingle, Charlotte Ahern, Sylvain Baruchel, Joel M. Reid, Scott Borinstein, Susan M. Blaney, Julia Glade Bender
CCR Translation for This Article from A Phase I Trial and Pharmacokinetic Study of Aflibercept (VEGF Trap) in Children with Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d2d7c4fd112653a589fdffa46182eff
https://doi.org/10.1158/1078-0432.22447025
https://doi.org/10.1158/1078-0432.22447025
Autor:
Julie R. Park, Peter C. Adamson, Brenda Weigel, Alice Chen, Darrell J. Yamashiro, Ashish M. Ingle, Charlotte Ahern, Sylvain Baruchel, Joel M. Reid, Scott Borinstein, Susan M. Blaney, Julia Glade Bender
Purpose: Aflibercept is a novel decoy receptor that efficiently neutralizes circulating VEGF. A pediatric phase I trial was conducted to define the dose-limiting toxicities (DLT), maximum tolerated dose (MTD), and pharmacokinetics (PK) of aflibercept
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24dd1860bcefba46f2fd49b630d743f9
https://doi.org/10.1158/1078-0432.c.6520952
https://doi.org/10.1158/1078-0432.c.6520952
Autor:
Susu Zhang, Jing Wang, Qi Liu, Hayes McDonald, Monica Bomber, Hillary Layden, Jacob Ellis, Scott Borinstein, Scott Hiebert, Kristy Stengel
Publikováno v:
Cancer Research. 82:2362-2362
Background: Gene expression networks are perturbed in every human malignancy. One common way that this occurs is through chromosomal translocations such as the the t(2;13)(q35;q14), which creates the oncogenic transcription factor, PAX3-FOXO1, in alv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e8edf11d280c557f01b576e1554816fe
https://doi.org/10.1158/1538-7445.am2022-2362
https://doi.org/10.1158/1538-7445.am2022-2362